Merck Signs a ~$493M Deal with Cyprumed to Develop Oral Peptide Therapeutics

Shots: Cyprumed & Merck have entered into a non-exclusive license & option agreement to develop oral formulations of Merck’s peptides, leveraging Cyprumed’s innovative drug delivery tech As per the deal, Merck has secured non-exclusive global rights to Cyprumed’s oral peptide delivery platform for an undisclosed number of targets, with an option to exclusively license it…

ByRidhi RastogiApril 15, 2025

NEWS

Astellas Collaborates with Chromatin Bioscience to Develop Cell-Selective Synthetic Promoters

Shots: Astellas has entered into a collaboration agreement with Chromatin Bioscience to design cell-selective synthetic promoters As per the agreement, Chromatin will utilize its chromatinLENS platform to develop cell-selective synthetic promoters for Astellas’ target profile, allowing precise & durable gene expression in specific cells chromatinLENS platform identifies gene regulatory elements from the dark genome &…

ByRidhi RastogiApril 14, 2025

NEWS

KalVista Pharmaceuticals Partners with Kaken Pharmaceutical to Commercialize Sebetralstat in Japan

Shots: Kaken Pharmaceutical has entered into a licensing agreement with KalVista Pharmaceuticals to obtain commercialization rights of sebetralstat in Japan As per the deal, KalVista will receive $11M upfront & $13M in regulatory (expected in early 2026) & commercial milestones, along with Japan NHI price-based royalties, with royalty rate as sales % approximately in the…

ByRidhi RastogiApril 9, 2025

NEWS

Ethris Partners with Lonza to Develop Intranasal Spray-Dried mRNA Vaccines Against Respiratory Diseases

Shots: Ethris has entered into a collaboration agreement with Lonza to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates designed for mucosal delivery in pts with respiratory diseases As per the deal, Lonza will support Ethris’ vaccine candidates, which are based on Ethris’ stabilized non-immunogenic mRNA (SNIM RNA) & stabilized lipid nanoparticles (SNaP LNP)…

ByRidhi RastogiApril 7, 2025

NEWS

Luye Pharma Launches Erzofri in the US for Schizophrenia and Schizoaffective Disorder

Shots: Luye Pharma has launched Erzofri extended-release injectable suspension in the US to treat adults with schizophrenia & as monotx. or adjunct therapy for adults with schizoaffective disorder Erzofri was approved by the US FDA based on a multiple-dose, parallel-group study evaluating its PK profile & relative bioavailability at steady state vs reference product, demonstrating…

ByRidhi RastogiApril 7, 2025

NEWS

ABL Bio Licenses Grabody-B Brain Delivery Platform to GSK for ~$2.76B (£2.15B)

Shots: ABL Bio has entered into a global licensing agreement with GSK for its Grabody-B BBB shuttle platform to develop therapies targeting various novel pathways using antibodies, siRNA, & ASOs for neurodegenerative diseases As per the deal, GSK will handle preclinical & clinical activities, manufacturing, & marketing of the potential programs in exchange for ~$99.4M,…

ByRidhi RastogiApril 7, 2025

NEWS

Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid

Shots: Sangamo has granted Eli Lilly global exclusive license of STAC-BBB for one initial CNS target, with an option to add up to 4 more targets upon payment of additional license fees, allowing IV delivery of Lilly’s genomic medicines for CNS diseases As per the deal, Lilly will handle R&D, regulatory activities, manufacturing, & global…

ByRidhi RastogiApril 4, 2025

EVENTS

Reuters Pharma 2025: Pre-Conference Talks Featuring Konrad Dobschuetz

Konrad Dobschuetz, Founder Director at Leap Advisory & Intelligence will be conducting a workshop at the upcoming Reuters Events Pharma 2025 on the topic “Patient Centricity”. In the exclusive discussion with PharmaShots, Konrad addresses the need for biopharma companies to achieve a patient mindset to deliver patient-centric care and enhance the patient experience. Konrad believes…

BySaurabh ChaubeyApril 4, 2025

NEWS

Sanofi Licenses an Undisclosed Nurix Therapeutics’ Drug Program for Autoimmune Diseases

Shots: Sanofi has licensed an undisclosed Nurix program targeting a previously undruggable transcription factor for autoimmune diseases under their Dec 2019 deal As per the deal, Nurix used its DEL-AI platform to develop E3 ligase-targeting degraders, with Sanofi having rights to license them. Nurix can co-develop & co-promote up to 2 US products, sharing US…

ByRidhi RastogiApril 3, 2025

NEWS

Lexicon Enters a Global Licensing Agreement with Novo Nordisk for LX9851

Shots: Lexicon has granted Novo Nordisk exclusive global rights to develop, manufacture & commercialize LX9851 (oral ACSL5 inhibitor) in all indications As per the deal, Lexicon will receive $45M upfront, ~$485M in regulatory & launch milestones, ~$475M in sales milestones, & tiered royalties from single to low-double-digit % of annual net sales. Lexicon will complete…

ByRidhi RastogiApril 2, 2025

Merck Signs a ~$493M Deal with Cyprumed to Develop Oral Peptide Therapeutics

Astellas Collaborates with Chromatin Bioscience to Develop Cell-Selective Synthetic Promoters

KalVista Pharmaceuticals Partners with Kaken Pharmaceutical to Commercialize Sebetralstat in Japan

Ethris Partners with Lonza to Develop Intranasal Spray-Dried mRNA Vaccines Against Respiratory Diseases

Luye Pharma Launches Erzofri in the US for Schizophrenia and Schizoaffective Disorder

ABL Bio Licenses Grabody-B Brain Delivery Platform to GSK for ~$2.76B (£2.15B)

Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid

Reuters Pharma 2025: Pre-Conference Talks Featuring Konrad Dobschuetz

Sanofi Licenses an Undisclosed Nurix Therapeutics’ Drug Program for Autoimmune Diseases

Lexicon Enters a Global Licensing Agreement with Novo Nordisk for LX9851

Contact US

FOLLOW US